Introduction {#s1}
============

Influenza may cause significant morbidity and mortality, especially in infants and children [@pone.0092500-Poehling1]--[@pone.0092500-Thompson1], who tend to exhibit high viral loads and prolonged viral shedding [@pone.0092500-Nicholson1], [@pone.0092500-Esposito1], [@pone.0092500-Frank1]. In paediatric patients, influenza may also evoke a wide range of nonspecific symptoms, which are often difficult to predict or quantify [@pone.0092500-Esposito1],[@pone.0092500-Gavin1]. Much progress has been made with respect to rapid influenza diagnostic testing (RIDT), but standardized assessments for the longitudinal monitoring of influenza infections are currently lacking.

Ideally, influenza infections would be monitored in real-time, at the point-of-care (POC). Immediate assessments would be particularly important in the inpatient setting and during the peak of flu season, when infection control measures are increasingly challenging and many different physicians may be assessing the patient over time. In influenza patients receiving antiviral therapy, an objective POC measure of viral load should be able to discriminate treatment success from virologic failure, which may contribute to the emergence of drug resistance [@pone.0092500-Rath1]. WHO and CDC guidelines recommend extending the duration of antiviral therapy beyond five days in influenza patients with evidence of ongoing viral replication, immuno-compromise or severe illness (i.e. ICU-level care) [@pone.0092500-WHOEURO1], [@pone.0092500-Fiore1]. Considering the possibility of antiviral resistance and viral rebound with premature termination of treatment, simple means of estimating viral clearance in high-risk patients are needed [@pone.0092500-Rath1], [@pone.0092500-Stephenson1]--[@pone.0092500-Lee2]. Furthermore, clinical trials evaluating newly developed antivirals will require objective parameters to evaluate antiviral efficacy compared to, or in combination with, currently available drugs [@pone.0092500-vanderVries1], [@pone.0092500-Siqueira1].

Molecular methods and viral culture are the most commonly used methods for the assessment of viral shedding in influenza patients [@pone.0092500-Pongthanapisith1], [@pone.0092500-Grijalva1]. These assays usually require considerable laboratory equipment and staff, and test results may take several days to become available to the physician [@pone.0092500-Gavin1], [@pone.0092500-Pongthanapisith1]. RIDT has been developed for the immediate diagnosis of influenza infections in the acute care setting [@pone.0092500-Grijalva1]--[@pone.0092500-Weitzel1]. RIDT are most sensitive with CT values \<30 [@pone.0092500-Rath2]. Second-generation RIDT (such as the SOFIA) use fluorescence-labelled antigens combined with POC readers, providing the advantage of standardized readouts. Evaluations in the US, Asia and Germany revealed improved sensitivities of up to 88% compared to RT-PCR with specificities close to 100% [@pone.0092500-Rath2]--[@pone.0092500-Lee3]. Rapid antigen tests reflect the actual amount of viral particles in a given sample, and tend to correlate well with viral culture results [@pone.0092500-Lewandrowski1], [@pone.0092500-Cho1]. PCR-based methods on the other hand, include an amplification step and are highly sensitive to the presence of nucleic acid. With the exception of capped m-RNA PCR, standard RT-PCR methods are not as specific for the presence of fully intact and infectious virus particles. An ideal POC test for the longitudinal follow-up of laboratory-confirmed influenza infections should therefore measure disease activity based on a critical amount of infective virus, even at the expense of lower sensitivities compared to PCR. Rapid antigen test may be able to fill this gap. During the process of viral clearance, the loss of antigen-positivity may indicate successful treatment or "overcoming" of natural infection, whereas RT-PCR results tend to remain positive for extended periods of time, even beyond resolution of clinical symptoms [@pone.0092500-Rath1].

We hypothesized that *qualitative* ("positive"/"negative") as well as *quantitative* ("signal over control") luminescent readouts from second-generation rapid antigen tests may prove to be useful as an immediate estimate of virus burden and disease activity. We used SOFIA as an example of a simple rapid antigen test that can be performed by nurses or doctors at the bedside.

The present study aims to evaluate the utility of:

i.  "[R]{.ul}apid [I]{.ul}nfluenza [F]{.ul}ollow-up [T]{.ul}esting" (RIFT) for the (qualitative) monitoring of influenza infections over time as well as

ii. "[Q]{.ul}uantitative [I]{.ul}nfluenza [F]{.ul}ollow-up [T]{.ul}esting" (QIFT) as a potential biomarker for the monitoring of influenza disease activity (virus burden) at the POC.

Methods {#s2}
=======

Ethics Statement {#s2a}
----------------

Ethical approval was obtained from the Charité Institutional Review Board (EA 24/008/10). Informed consent procedures were waived for enhanced patient monitoring in the context of a quality management (QM) program.

Study design and data collection {#s2b}
--------------------------------

This prospective evaluation study was performed in the context of a QM program at the Charité Department of Paediatrics in collaboration with the National Reference Centre for Influenza at the Robert Koch Institute (RKI). From October 1, 2011 to April 30, 2013, all patients fulfilling pre-defined criteria for influenza-like illness (fever ≥38°C and ≥ one respiratory sign or symptom) were assessed consecutively by a specifically trained QM team [@pone.0092500-Rath1], [@pone.0092500-Rath2]. Cases were included if i) the patient was 0--18 years of age, and ii) influenza infection was confirmed by RT-PCR in the national reference laboratory. Cases were excluded from this analysis in case of: i) simultaneous infection with more than one influenza type or subtype [@pone.0092500-Rath3], or ii) inability to obtain nasopharyngeal samples.

Follow-up Testing {#s2c}
-----------------

Members of a specifically trained QM team obtained nasopharyngeal samples, with rapid antigen tests (SOFIA) performed at the bedside. Patients with laboratory-confirmed influenza were scheduled for follow-up testing every two to three days, until at least one negative RIFT result was obtained or longer, if indicated. Basic clinical parameters and treatment with neuraminidase inhibitors were recorded. The respective clinician on duty made antiviral treatment decisions independently. With each rapid antigen test, blinded RT-PCR was performed in parallel at the RKI.

### RIFT {#s2c1}

Fluorescence-based RIFT was performed immediately at the POC and according to the manufacturer\'s protocol for the *SOFIA Influenza A+B FIA* test kit (Quidel Inc., San Diego, CA, USA). With each test, the SOFIA luminescent reader provided print-outs with qualitative test results (influenza A or B positive/negative), which were recorded and communicated without delay to the patient or parent as well as to the physician on duty.

### QIFT {#s2c2}

QIFT-values were calculated for each rapid antigen test based on the relationship between the influenza A and B test lines\' fluorescence intensities and the cut-offs for each analyte with the SOFIA test. The resulting signal over control values (SCo) generated by the SOFIA POC reader ranged from 0 to 400. The limit of detection (LOD) with QIFT is 1; values \>1 were considered positive.

### RT-PCR and Viral Load (VL) Determination {#s2c3}

Qualitative and quantitative RT-PCR were performed as described recently [@pone.0092500-Rath1]. Briefly, nasopharyngeal swabs were washed out in cell culture medium and RNA was extracted either by using the MagAttract Viral RNA 48 Kit (Qiagen), the RTP RNA/DNA Virus Minikit (Invitek), or the MagnaPure 96 DNA and viral NA small volume kit (Roche). After random reverse transcription complementary DNA, primer and probes targeting the M, HA and NA genes were used for detection and further subtyping of influenza [@pone.0092500-Schulze1]. The RT-PCR cycle threshold (CT) values obtained for each influenza positive sample were analysed comparatively with serially diluted plasmid standards. All reactions were performed using the Light Cycler 480 real-time PCR system (Roche). CT values obtained with influenza negative samples were defined as 45 for mathematical analyses. The limit of detection for RT-PCR (LOD~PCR~) depends on the targeting gene and was determined to be 2--15 genome equivalents per reaction (95% detection probability) [@pone.0092500-Schulze1]. Regarding dilution factors due to sample preparation, RNA extraction, cDNA synthesis, and PCR performing, the limit of viral load quantitation (LOQ) was estimated to be 1000 copies/ml. This value was defined as LOD~VL~, below which the calibration curve is no longer valid and quantitative values are not reliable. Comparison of virus load assessments based on CT versus quantitative PCR at the National Reference Centre showed a correlation of 0.95 (Spearman, p-value\<0.0001; [Figure S1](#pone.0092500.s001){ref-type="supplementary-material"}). With a high correlation between the two methods of VL assessment in the reference laboratory, it was decided to use CT for the QIFT/PCR correlation analyses, with the advantage of a lower LOD~PCR~ compared to LOD~VL~.

Data Analysis {#s2d}
-------------

Data analysis and reporting were conducted in accordance with the STARD guidelines [@pone.0092500-Bossuyt1], wherever applicable. The STARD checklist is provided in the Supplementary Materials ([Text S1](#pone.0092500.s002){ref-type="supplementary-material"}). The STARD was chosen as the most appropriate standard available, even though the reported study pertains to longitudinal follow-up of patients with *established* diagnoses rather than diagnostic accuracy. The diagnostic accuracy including sensitivities and specificities of SOFIA RIDT in relation to PCR in the same setting has been published elsewhere [@pone.0092500-Rath2].

### RIFT compared to longitudinal PCR results {#s2d1}

All patients with at least one positive RIFT and completed follow-up series were included in the analysis. Qualitative RIFT data for each patient during follow-up were compared to the corresponding CT value in the RT-PCR.

Three key time points were determined for each disease episode:

i.  T~MV~  =  Time point of maximum viral load/ lowest CT

ii. T~LP~  =  Time point of last positive RIFT

iii. T~FN~  =  Time point of first negative RIFT.

The respective time points T~MV~, T~LP~, and T~FN~ were plotted against the respective CT values at T~MV~, T~LP~, and T~FN.~ The y-axis was inserted at the time point where the switch from T~LP~ to T~FN~ occurred ( = "Switch Day").

### RIFT compared to viral culture {#s2d2}

Overall rates of agreement and kappa scores were calculated (Stata Version 11.2), comparing the time period required for RIFT and viral culture to become negative, respectively.

### QIFT and clinical parameters {#s2d3}

For correlation analysis between QIFT and clinical presentation, the following clinical parameters were chosen: a) maximum body temperature, b) CRP and c) presence of tachypnea (according to age-adjusted WHO criteria).

Correlation analyses for a) and b) were conducted using the Spearman rank correlation test. For analysis of c), a non-parametric test (Mann Whitney) was used.

### QIFT /PCR Correlation Analysis {#s2d4}

For QIFT/PCR correlation analysis, two correlation plots were generated:

i.  First, all values were included. Any QIFT values \< LOD~QIFT~ were set equal to the LOD~QIFT~ as the most conservative estimate. Values  = 0 (i.e. virus not detectable by either method) were set to 0.

ii. A second analysis was performed excluding any values \< LOD.

Correlation analyses between continuous variables were conducted using the Spearman rank correlation test.

### Categorizing viral load based on QIFT {#s2d5}

Binning analyses were performed for the categorization ("binning") of median virus load in relation to different QIFT categories (negative, low, moderate, and high QIFT). Continuous variables were compared between different categories ("bins") using non-parametric tests (Mann Whitney, Kruskal Wallis).

For comparison between QIFT and CT values, a "sliding window plot" was generated using MATLAB 7.14 (MathWorks Inc., Natick, MA): All simultaneous measurements of QIFT vs. CT were sorted by the respective QIFT in ascending order. Every 30 consecutive QIFT values denote a sliding window.

### Estimating viral load kinetics based on QIFT and PCR {#s2d6}

Lacking a reference standard for the assessment of viral shedding/antigen clearance over time, overall rates of agreement and kappa scores were calculated comparing QIFT increase or decrease to PCR increase or decrease over time [@pone.0092500-Biswas1]--[@pone.0092500-Dunn1]. Each sequence of 2 consecutive samples from the same patient was included in the analysis. A trend in viral load was defined as increase or decrease if rates of change in relation to the previous measurement in the same patient exceeded 10%.

### Viral clearance dynamics with and without treatment {#s2d7}

Viral clearance dynamics with and without treatment were computed for VL (CL~VL~) and QIFT (CL~QIFT~). All cases with at least two positive samples with both VL and QIFT measurements available ( = QIFT population) were included. In patients receiving antivirals, treatment had to be completed and baseline swabs had to be obtained within 24 hours of treatment initiation. Patient-specific CL~VL~ and CL~QIFT~ were estimated with calculated quantitative values even below LOD, using the optimization routine *lsqcurvefit* in MATLAB version 7.10 (MathWorks Inc., Natick, MA) and a weighted least-square criterion to minimize residual error. Details are provided in the [Text S2](#pone.0092500.s003){ref-type="supplementary-material"}.

Results {#s3}
=======

Study population {#s3a}
----------------

From October 1, 2011 to April 30, 2013, a total number of 2048 disease episodes were assessed and documented prospectively; of these, 278 (13.6%) cases were laboratory-confirmed for influenza by PCR. Three cases with dual influenza infection (A/A, A/B and B/B) and two patients unable to provide nasopharyngeal samples were excluded, leaving for analysis 273 cases of laboratory-confirmed influenza with serial swabs available. (Two patients experienced two independent disease episodes due to different influenza viruses, both were included as separate cases in the analysis.)

Case characteristics at the time of enrolment with each disease episode are displayed in [Table 1](#pone-0092500-t001){ref-type="table"}. Among 273 influenza cases ( = total population) 55 were "late presenters", i.e. patients who appeared in the emergency room late in the course of illness, after loss of their antigen-positive status in the RIFT, which usually requires intact viral particles (as opposed to nucleic acid) and higher viral loads compared to PCR. Overall, 178 patients completed the full follow-up program until at least one negative RIFT was obtained (RIFT population), resulting in an overall completion rate of 85%. For QIFT/PCR correlation and binning analyses, all 669 quantitative antigen measurements were included. A total of 210 cases fulfilled QIFT population criteria (availability of \> = 2 positive samples with both, VL and QIFT measurements). Among these, 183 patients were without antiviral therapy, and 27 completed oseltamivir therapy. There was no significant correlation between the decision to use antivirals and either the number of symptoms, the duration of illness, or the presence of underlying conditions (p = 0.595, p = 0.781 and p = 0.797, respectively).

10.1371/journal.pone.0092500.t001

###### Characteristics of eligible PCR- confirmed influenza cases.

![](pone.0092500.t001){#pone-0092500-t001-1}

  Category                                          Subcategory                   Total cases   Age \<2 years   Age 2--5 years   Age \>5 years
  -------------------------------- --------------------------------------------- ------------- --------------- ---------------- ---------------
  **Total N**                                                                         273            82               96              95
  **Gender**                                           male                           152            47               49              56
                                                                                    (55.7)         (58.3)           (51.0)          (58.9)
                                                      female                          121            35               47              39
                                                                                    (44.3)         (42.7)           (49.0)          (41.1)
  **Underlying condition**                           pulmonary                        26              7               7               12
                                                                                     (9.5)          (8.5)           (7.3)           (12.6)
                                                      cardiac                         20              4               7                9
                                                                                     (7.3)          (4.9)           (7.3)            (9.5)
                                                     endocrine                        13              1               4                8
                                                                                     (4.8)          (1.2)           (4.2)            (8.4)
                                                    hepatorenal                        4              1               0                3
                                                                                     (1.5)          (1.2)           \(0\)            (3.2)
                                                    neurologic                        19              3               6               10
                                                                                     (7.0)          (3.7)           (6.3)           (10.5)
                                                immuno- suppression                    9              0               2                7
                                                                                     (3.3)          \(0\)           (2.1)            (7.4)
                                                    hematologic                        2              1               0                1
                                                                                     (0.7)          (1.2)           \(0\)            (1.1)
                                    Prematurity[a](#nt101){ref-type="table-fn"}       33             13               13               7
                                                                                    (12.1)         (15.9)           (13.5)           (7.4)
  **Treatment with Oseltamivir**                      treated                         33             16               11               6
                                                                                    (12.1)         (19.5)           (11.5)           (6.3)
                                                     untreated                        240            66               85              89
                                                                                    (87.9)         (80.5)           (88.5)          (93.7)
  **Influenza type/ subtype**                      A(H1N1)pdm09                       70             27               23              20
                                                                                    (25.6)         (32.9)           (24.0)          (21.1)
                                                      A(H3N2)                         112            38               47              27
                                                                                    (41.0)         (46.3)           (49.0)          (28.4)
                                                         B                            91             17               26              48
                                                                                    (33.3)         (20.7)           (27.1)          (50.5)

\<37 gestation weeks.

Data Analysis {#s3b}
-------------

### RIFT results tend to turn negative prior to PCR {#s3b1}

The qualitative results obtained with rapid influenza follow-up testing (RIFT) were compared to cycle thresholds with RT-PCR. The key follow-up time points T~MV~, T~LP~, and T~FN~ were determined for each disease episode and plotted against the corresponding CT values, as depicted in [Figure 1](#pone-0092500-g001){ref-type="fig"}.

![Comparison of CT values over time in relation to RIFT.\
The insertion of y-axis reflects the "switch" from positive to negative RIFT.](pone.0092500.g001){#pone-0092500-g001}

During follow-up visits, the first negative RIFT was observed at a median of 8 days (range 2; 19) with a median CT of 37 (range 45; 23) and a median VL of 5.6×10∧3 (range 0; 78.4×10∧3). The first negative RIFT result was consistently observed prior to (68%) or simultaneous with (30%) a first negative RT-PCR result. There were only 4 instances (2%) where a positive RIFT was not confirmed by PCR, which was attributed to contamination of infant samples with RNAses. No cases of viral rebound were observed. The "Switch Day" from positive to negative RIFT, illustrated by insertion of the y-axis between T~LP~ and T~FN~, corresponded to a CT value of 33.

RIFT results correlate well with virus culture {#s3c}
----------------------------------------------

In 118 cases, at least two swabs with viral culture data in addition to RIFT were available, with a "switch" from positive RIFT and/or culture to negative RIFT and/or culture. Time required for RIFT to become negative from a previously positive value was 5.97±3.16 days; (range 2; 18).Time required for viral culture to become negative was 5.31±2.67 days (range 2; 14).

We observed an overall rate of agreement of 77.97% between the time period required for RIFT to become negative and time period required for viral culture to become negative (kappa = 0.75; p-value\<0.0001). With respect to correlation analysis between time periods, we observed a Spearman\'s correlation of 0.803 between the two time periods (p-value\<0.0001).

### No significant correlation between QIFT values and clinical parameters {#s3c1}

QIFT showed no significant correlation or association to the following clinical parameters: a) maximum body temperature (Spearman Rho = −0.027, p = 0.667), b) CRP (Spearman Rho = −0.087, p = 0.338) and c) presence of tachypnea (Mann Whitney, p = 0.154).

### QIFT values close to the LOD correlate poorly with PCR {#s3c2}

All quantitative measurements obtained during longitudinal follow-up amounted to 669 measurements with QIFT and matching CT values. QIFT/PCR correlations are depicted in [Figure 2](#pone-0092500-g002){ref-type="fig"}. QIFT showed a significant correlation with CT of 0.69 (Spearman, p-value\<0.0001) with QIFT values \< LOD set to LOD  = 1 as the most conservative estimate. Following the RIFT observations illustrated above, it is expected that during longitudinal follow-up (of which all values are included in this plot), RIFT will turn negative prior to PCR. [Figure 2](#pone-0092500-g002){ref-type="fig"} illustrates that QIFT values near or below the LOD~QIFT~ correlated poorly with PCR, compared to higher QIFT values.

![Comparison of CT versus QIFT.\
LOD~QIFT~ was defined as QIFT = 1.](pone.0092500.g002){#pone-0092500-g002}

### Categorization based on QIFT provides useful estimate of virus burden {#s3c3}

For the categorization of virus load based on low, moderate and high QIFT values, binning analyses were performed: QIFT readings were categorized into the following "bins": "negative" (0--1), "low" (i.e. \>1--100), "moderate" (\>100--199), and "high" (\>199--400). Median CT values differed significantly with respect to the four QIFT categories (Mann Whitney, Kruskal Wallis, p-value\<0.0001), see [Figure 3](#pone-0092500-g003){ref-type="fig"}.

![Binning analysis: Estimation of CT, median values based on categorized QIFT readouts.\
The following QIFT categories were used: "Negative QIFT": 0 to 1 (n = 333). "Low QIFT": \>1 to 100 (n = 254). "Moderate QIFT": \>100 to 199 (n = 56). "High QIFT": \>199 (n = 26).](pone.0092500.g003){#pone-0092500-g003}

A Sliding Window Plot was generated to evaluate the performance of any particular QIFT in predicting CT values ([Figure 4](#pone-0092500-g004){ref-type="fig"}). The resulting graph illustrates a percentiles curve for the estimation of CT based on QIFT, including medians for the respective QIFT value. Please note that with 669 samples, there is a relatively broad coefficient of variation of approximately 20%.

![Sliding Window Graph: Binning of median CT values and ranges/percentiles based on median QIFT.](pone.0092500.g004){#pone-0092500-g004}

### Up- and downward trends in virus load are reflected similarly by PCR and QIFT {#s3c4}

To determine trends in virus burden based on quantitative PCR versus QIFT, rates of agreement between "QIFT-increase", "QIFT-decrease", "VL-increase", and "VL-decrease" were calculated. Overall agreement was 88% (kappa = 0.49; p-value\<0.0001), see [Table 2](#pone-0092500-t002){ref-type="table"}.

10.1371/journal.pone.0092500.t002

###### Rates of agreement between QIFT and VL increase/decrease.

![](pone.0092500.t002){#pone-0092500-t002-2}

                       QIFT ↑    QIFT ↓   
  ------------------- --------- --------- ---------
  VL ↑                   29        31     
  VL ↓                   16        320    
  Rate of Agreement    **64%**   **91%**   **88%**

Viral clearance rates in treated and untreated patients may be monitored using QIFT {#s3d}
-----------------------------------------------------------------------------------

Median clearance rates CL~VL~ and CL~QIFT~ in QIFT patients with and without antiviral treatment are depicted in [Figure 5](#pone-0092500-g005){ref-type="fig"}.

![Comparison of viral clearance rates for CL~VL~ versus CL~QIFT~ and for treated versus untreated patients.\
Variance in viral clearance rates for quantitative is smaller in treated than in untreated patients, for both VL and QIFT.](pone.0092500.g005){#pone-0092500-g005}

Overall, CL~QIFT~ showed slightly lower, but similar values compared to CL~VL~. In treated patients, median clearance rates were 1.02/day when determined by PCR (CL~VL~), and 0.56/day when measured by QIFT (CL~QIFT~) (Spearman: 0.26; p = 0.1912). In untreated cases, the median CL~VL~ was 0.97/day and median CL~QIFT~ was 0.76/day (Spearman: 0.24; p = 0.0013). In patients receiving antiviral therapy, viral clearance rates based on PCR (CL~VL~) showed less variability (range 0.08; 2.49) compared to untreated patients (range −4.70; 4.84). The same observation held true with respect to viral clearance rates based on antigen testing (CL~QIFT~) ranging from −0.07 to 1.62 and from −2.36 to 5.03 in treated *versus* untreated patients, respectively.

Discussion {#s4}
==========

Statement of Principal Findings {#s4a}
-------------------------------

We report a first prospective study investigating "loss of antigen positivity" as a POC parameter for the longitudinal monitoring of influenza patients. During follow-up, rapid antigen testing using fluorescence-based laminar flow tests (RIFT) may provide a practical surrogate measure for influenza disease activity. "Loss of antigen positivity" in RIFT may indicate a drop in viral load below a critical threshold, where viral rebound is no longer expected. It may also indicate loss of infectivity as reflected by viral culture turning negative simultaneously with RIFT in most cases.

Quantitative readouts from the same rapid test (QIFT) show potential as a valuable biomarker for the monitoring of virus burden over time, with the advantage of obtaining results immediately at the POC. QIFT may also be able to discriminate between disease progression (VL increase) and resolution (VL decrease). In patients receiving antiviral therapy, QIFT can be used to monitor treatment success *versus* failure and/or risk of antiviral drug resistance by estimating viral clearance rates under therapy [@pone.0092500-Rath1].

Rapid Follow-up Testing in Context {#s4b}
----------------------------------

For effective infection control measures and to reduce morbidity and mortality, isolation precautions are imminent. Antiviral treatment when indicated needs to be initiated as timely as possible [@pone.0092500-Fiore1], [@pone.0092500-Committee1]. The need to diagnose treatable conditions with high disease burden has driven the development of diagnostic assays to be used at the POC. In contrast to first-generation RIDT, where sensitivities were still relatively low and user-dependent [@pone.0092500-Moore1], second-generation RIDT combine improved sensitivities with objective automated read-outs [@pone.0092500-Rath2], [@pone.0092500-Lewandrowski1], [@pone.0092500-Lee3].

Recent fluorescent-based RIDT such as SOFIA issue *qualitative* (positive/negative) results based on *qualitative* signal over control measurements. While RIDT have been licensed for the initial diagnosis of influenza at the POC [@pone.0092500-Poehling1], [@pone.0092500-Gavin1], [@pone.0092500-Bonner1], this pilot study demonstrates that *qualitative* (RIFT) and *quantitative* (QIFT) fluorescence-based antigen testing may both be useful for the longitudinal monitoring of influenza infections over time.

Strengths and Limitations of the Study {#s4c}
--------------------------------------

The retention rate in this study was \>85%, which is very high for an observational setting. For the evaluation of rapid influenza testing as a follow-up tool (RIFT) and QIFT-based clearance rates however, a sufficient number of follow-up time points was required. Hence, smaller subsets of patients were included in these analyses, representing 65% in RIFT and 80% in QIFT clearance rate calculations.

During longitudinal follow-up, RIFT turned negative consistently with, or after the PCR. It has to be borne in mind, that PCR and antigen tests measure different aspects of the same disease. While PCR-based (amplification) methodologies may be sensitive enough to detect even small amounts of nucleic acid over extended periods of time, direct antigen testing may provide an immediate (linear) estimate of virus burden during the acute phase of the disease only. It has been known that RIDT correlate better with viral culture than with PCR. It was therefore expected that the agreement between RIFT and PCR would decline during longitudinal follow-up (until both test are negative), whereas the duration of viral culture positivity may correlate well with antigen positivity [@pone.0092500-Lewandrowski1], [@pone.0092500-Cho1]. It is also to be expected that the lower sensitivity of rapid antigen testing compared to PCR would affect the QIFT/PCR correlation, especially later during the course of illness, when "loss of antigen positivity" has already occurred and RIFT has turned negative ( = QIFT\<1). VL measurements from PCR-positive samples below the LOD~QIFT~ could however not be quantified reliably. For utmost transparency, values below the LOD~QIFT~ were included in the analyses, but set to equal the highest possible value ( =  LOD) as the most conservative estimate. Reversely, negative QIFT corresponded well with negative PCR results.

QIFT and PCR both rely on the semi-quantitative measurement of virus load in nasopharyngeal samples -- unlike in the case of HIV and hepatitis VL monitoring, where *plasma* virus loads are followed. To minimize variability with nasopharyngeal sampling, all RIFT/QIFT assays were performed immediately at the POC, and by a specifically trained QM team. Samples were delivered immediately to the RKI for blinded PCR analyses. The value of optimized sampling procedures has been demonstrated in previous evaluations establishing the sensitivity and specificity of the same assay (SOFIA for influenza A and B) in the same QM setting [@pone.0092500-Rath2]. Use of QIFT and RIFT in less controlled settings may yield different results. Even if sampling has been optimized however, it must be noted that nasopharyngeal samples may not always reflect the virus burden present in the lower respiratory tract in critically ill patients, where VL may be elevated in patients infected with influenza viruses [@pone.0092500-Lee1], [@pone.0092500-vanRiel1]. Also, viral shedding in the lower airways is known to be prolonged in adult patients with pneumonia or immuno-compromise. In these patients, relapse of disease can occur if therapy is stopped based on cessation of upper airway replication alone [@pone.0092500-Lee1]. This however, would require broncho-alveolar lavage procedures, which would neither be ethical nor feasible for the routine follow-up of paediatric influenza patients (unless intubated and critically ill). The present study does not allow for comparison of specific patient subpopulations. Further research in specific risk groups is needed.

Future analyses in specific subpopulations may compare the 3-way relationship between of PCR-positivity, antigen-positivity and viral culture in influenza patients with extreme disease presentations or different levels of immunosuppression.

Future Perspectives {#s4d}
-------------------

The results of the binning analyses demonstrate the practical value of QIFT for the monitoring of influenza disease activity at the POC. For QIFT to be used in clinical practice in the future, quantitative readings should be issued as four categories: negative, low, moderate, and high virus burden. QIFT as a follow-up tool could be optimized further, if the fluorescent reader provided a standardized display of trends in virus burden in relation to previous measurements in the same patient, or VL estimates as demonstrated in the binning and sliding window plots. Having immediate estimates of virus burden available at the POC will be of great value to support a personalized approach to the management of infants and immuno-compromised individuals with influenza infection who often exhibit elevated virus titres and prolonged virus shedding [@pone.0092500-Nicholson1], [@pone.0092500-Esposito1], [@pone.0092500-Frank1]. Previous studies have shown that virus burden cannot be estimated based on clinical appearance alone. It has further been reported that viral shedding may persist beyond cessation of clinical symptoms [@pone.0092500-Esposito1], [@pone.0092500-Chin1]. Objective parameters such as RIFT and QIFT may facilitate individualized therapy of influenza with estimates of virus burden available immediately at the POC.

The decision whether or not to treat with antivirals in this QM setting, was left up to the clinician in charge. Interestingly, only a small proportion (12.1%) of patients with laboratory--confirmed influenza received neuraminidase inhibitor therapy. For all treated patients oseltamivir was prescribed. In the described setting, zanamivir is restricted to antiviral therapy in ICU patients or patients unable to take p.o. medicine. There was no evidence of correlation between treatment decision and patients\' clinical symptoms, underlying conditions or late appearance to the hospital. With new antivirals under development, it might be of value to pursue QIFT as a follow-up tool in randomized controlled clinical trials.

Current recommendations by health authorities regarding established neuraminidase inhibitor therapies include a standard five-day course of treatment with a possible extension to ten days in cases of "ongoing viral replication" [@pone.0092500-WHOEURO1], [@pone.0092500-Fiore1]. Once antiviral therapy has been terminated, it should not be restarted. This implies that the decision whether to stop or adjust antiviral therapy has to be made on day five, at the POC. Relative under-dosing and/or premature treatment termination harbour the risk of promoting antiviral drug resistance [@pone.0092500-Stephenson1], [@pone.0092500-Lee2].

Previous studies have indicated that during antiviral therapy, a less-than-expected slope of decline in VL might indicate resistance development [@pone.0092500-Rath1]. QIFT shows potential as a simple tool for the real-time monitoring of treatment success at the POC: QIFT-based viral clearance estimates (CL~QIFT~) showed similar ranges and percentiles compared to PCR-based VL estimates (CL~VL~). CL~VL~ however may be more accurate in lower ranges and with prolonged treatment. Further analyses in larger cohorts of treated influenza patients may be required to determine the exact relationship between CL~QIFT~ and CL~VL~. The interesting observation that antiviral treatment may reduce intra-individual variation in viral clearance rates with both CL~QIFT~ and CL~VL~ warrants further investigation.

Additional studies may be undertaken to investigate the cost-effectiveness of individualized antiviral therapy as well as the longitudinal monitoring of virus burden in infants, high risk and immuno-compromised individuals. The high retention rate in this QM program indicates that the availability follow-up data at the POC and the immediate feedback and reassurance to concerned patients and families may have a positive impact on patient satisfaction.

Conclusions {#s5}
===========

RIFT and QIFT show promise as simple and objective tools for the real-time monitoring of influenza infections over time. RIFT may be used as an objective measure for "loss of antigen positivity", whereas QIFT provides a useful estimate of viral clearance over time. The ability to monitor disease activity at the POC may have important implications for infection control. It may also facilitate the individualized management of infants and young children as well as immuno-compromised patients under antiviral therapy. Future studies in larger cohorts of patients will explore the practical implications of RIFT and QIFT in different clinical and demographic settings.
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**Comparison of CT versus VL determined by RT-PCR.** LOD~VL~ was defined as VL = 1000 copies/ml. Spearman Rho = 0.95 (p-value\<0.0001).
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**Calculation of viral clearances.**
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Click here for additional data file.
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